Developments in STD/HIV interactions: The intertwining epidemics of HIV and HSV-2

Steven J. Reynolds; Thomas C. Quinn

doi:10.1016/j.idc.2005.04.005

Developments in STD/HIV interactions: The intertwining epidemics of HIV and HSV-2

Steven J. Reynolds, Thomas C. Quinn

School of Medicine

Research output: Contribution to journal › Review article › peer-review

28 Scopus citations

Abstract

Antiviral agents aimed at treating HSV-2 chronically infected individuals have proven to be effective in the prevention of symptomatic genital herpes and the reduction of viral shedding. These agents play a key role in current HIV prevention trials that will assess the role of suppression of HSV-2 infection on the risk for HIV acquisition and transmission. An added clinical benefit of treating HSV-2/HIV-coinfected individuals is the potential survival benefit, as suggested by earlier studies and by the recent findings that HSV-2/HIV dually infected individuals have higher viral loads [32]. The results of the current HSV-2 suppression trials may provide additional tools to fight the global spread of HIV infection. Treatment of HSV-2/HIV dually infected individuals may prove to be a low-cost intervention to improve clinical outcomes and delay the need for antiretroviral therapy.

Original language	English (US)
Pages (from-to)	415-425
Number of pages	11
Journal	Infectious disease clinics of North America
Volume	19
Issue number	2 SPEC. ISS.
DOIs	https://doi.org/10.1016/j.idc.2005.04.005
State	Published - Jun 2005

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

Access to Document

10.1016/j.idc.2005.04.005

Cite this

@article{d66117cb931e42c0956d5e94ff243f34,

title = "Developments in STD/HIV interactions: The intertwining epidemics of HIV and HSV-2",

abstract = "Antiviral agents aimed at treating HSV-2 chronically infected individuals have proven to be effective in the prevention of symptomatic genital herpes and the reduction of viral shedding. These agents play a key role in current HIV prevention trials that will assess the role of suppression of HSV-2 infection on the risk for HIV acquisition and transmission. An added clinical benefit of treating HSV-2/HIV-coinfected individuals is the potential survival benefit, as suggested by earlier studies and by the recent findings that HSV-2/HIV dually infected individuals have higher viral loads [32]. The results of the current HSV-2 suppression trials may provide additional tools to fight the global spread of HIV infection. Treatment of HSV-2/HIV dually infected individuals may prove to be a low-cost intervention to improve clinical outcomes and delay the need for antiretroviral therapy.",

author = "Reynolds, {Steven J.} and Quinn, {Thomas C.}",

year = "2005",

month = jun,

doi = "10.1016/j.idc.2005.04.005",

language = "English (US)",

volume = "19",

pages = "415--425",

journal = "Infectious disease clinics of North America",

issn = "0891-5520",

publisher = "W.B. Saunders Ltd",

number = "2 SPEC. ISS.",

}

TY - JOUR

T1 - Developments in STD/HIV interactions

T2 - The intertwining epidemics of HIV and HSV-2

AU - Reynolds, Steven J.

AU - Quinn, Thomas C.

PY - 2005/6

Y1 - 2005/6

N2 - Antiviral agents aimed at treating HSV-2 chronically infected individuals have proven to be effective in the prevention of symptomatic genital herpes and the reduction of viral shedding. These agents play a key role in current HIV prevention trials that will assess the role of suppression of HSV-2 infection on the risk for HIV acquisition and transmission. An added clinical benefit of treating HSV-2/HIV-coinfected individuals is the potential survival benefit, as suggested by earlier studies and by the recent findings that HSV-2/HIV dually infected individuals have higher viral loads [32]. The results of the current HSV-2 suppression trials may provide additional tools to fight the global spread of HIV infection. Treatment of HSV-2/HIV dually infected individuals may prove to be a low-cost intervention to improve clinical outcomes and delay the need for antiretroviral therapy.

AB - Antiviral agents aimed at treating HSV-2 chronically infected individuals have proven to be effective in the prevention of symptomatic genital herpes and the reduction of viral shedding. These agents play a key role in current HIV prevention trials that will assess the role of suppression of HSV-2 infection on the risk for HIV acquisition and transmission. An added clinical benefit of treating HSV-2/HIV-coinfected individuals is the potential survival benefit, as suggested by earlier studies and by the recent findings that HSV-2/HIV dually infected individuals have higher viral loads [32]. The results of the current HSV-2 suppression trials may provide additional tools to fight the global spread of HIV infection. Treatment of HSV-2/HIV dually infected individuals may prove to be a low-cost intervention to improve clinical outcomes and delay the need for antiretroviral therapy.

UR - http://www.scopus.com/inward/record.url?scp=20444457566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20444457566&partnerID=8YFLogxK

U2 - 10.1016/j.idc.2005.04.005

DO - 10.1016/j.idc.2005.04.005

M3 - Review article

C2 - 15963880

AN - SCOPUS:20444457566

SN - 0891-5520

VL - 19

SP - 415

EP - 425

JO - Infectious disease clinics of North America

JF - Infectious disease clinics of North America

IS - 2 SPEC. ISS.

ER -

Developments in STD/HIV interactions: The intertwining epidemics of HIV and HSV-2

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this